Introduction: Immunotherapy is also called as biologic therapy or biotherapy. Immunotherapy is quickly becoming an important component in the multipronged approaches being developed to treat certain forms of cancer. The goal of immunotherapy is to strengthen the body's own natural ability to combat cancer by enhancing the effectiveness of the immune system. This study tries to compile response rates and side effect profile of Nivolumab. Methods: Patients with performance status of 3 or less than 3, who failed on 2 or more lines of therapy except melanoma and have received minimum 3 cycles of Nivolumab were taken in to this study. Study subjects followed for minimum of 3 cycles for assessment. Each patient received 240 mg of Nivolumab once in 15 days for 3 -6 cycles. Results: The median age of 20 patients was 53 years (26 -79 yrs). 18 patients were male and 2 patients were female. Progressive disease (PD) was observed in 12 patients with immunotherapy treatment and partial response (PR) was observed in 3 patients, and stable disease (SD) in 5 patients. Conclusion: This is one of the Indian study mainly reporting experiences with Nivolumab. Large sample size is required to conclude about the efficacy of the study. Nivolumab is more tolerated in Indian patients compared to other reported studies.
Open Journal of Immunology liam Coley started using immunotherapy in cancer where it is well founded in Asthma and Arthritis. One hallmark of cancer is immune evasion, in which the immune system does not mount an effective antitumor response [2] . Immunotherapy is also called as biologic therapy or biotherapy. Immunotherapy is quickly becoming an important component in the multipronged approaches being developed to treat certain forms of cancer. The landscape of cancer therapy has been recently transformed by the emergence of immunotherapy involving the targeting of immune checkpoints. The goal of immunotherapy is to strengthen the body's own natural ability to combat cancer by enhancing the effectiveness of the immune system [3] . There are three known main categories of immunotherapy: immune response modifiers (cytokines), monoclonal antibodies and vaccines [4] . Nivolumab (ONO-4538/BMS-936558/MDX-1106) is a fully human IgG4 monoclonal antibody that targets programmed cell death-1 (PD-1), one of the T-cell surface membrane receptors. Nivolumab received the world's first regulatory approval in Japan in July 2014 for the treatment of unresectable malignant melanoma. Nivolumab is also undergoing development for the treatment of other indications based on checkmate trails [5] . Nivolumab is approved by Food and Drug Administration (FDA) for Melanoma Non-Small Cell Lung Cancer (NSCLC), Renal Cell Carcinoma (RCC), Hodgkin Lymphoma, Head and Neck Cancer, Urothelial Carcinoma, Colorectal Cancer, and Hepatocellular Carcinoma (HCC) and approved with combination in other indications [6] . The maximal tolerated dose (MTD) for nivolumab has not been identified, and a similar safety profile has been demonstrated across tumour types and dose levels (0.1 -10 mg/kg). More recently FDA both 3 mg/kg nivolumab and 240 mg fixed dose are based on pharmacokinetic data [7] . This study explores response rates and side effect profile of Nivolumabin a single centre.
Methods
In this study, a total of 20 eligible patients who received Nivolumab in HCG Cancer Speciality Center from 2017 to March 2018 were prospectively analysed. Primary objective of this study was to assess the response rate of Nivolumab and evaluation of toxicity was secondary objectives.
Results
There were total 20 patients were included for the analysis and all patients were able to complete minimum 3 -4 cycles of Immunotherapy.
The median age of 20 patients was 53 years (26 -79 yrs). 18 patients were male and 2 patients were female. Immunotherapy is given as 1 st line in 6 patients and ≥2 lines in 14 patients. With regards to safety, all of our patients are well tolerated with immunotherapy except for grade 1/grade 2 anaemia/thrombocytopenia in 6 patients. Progressive disease (PD) was observed in 12 patients with immunotherapy treatment and partial response (PR) were observed in 3 patients, stable disease (SD) in 5 patients (Table 1 ).
Discussion
Immunotherapy is an advanced treatment for metastatic cancer, where it mainly involves with the body's natural immune response to cancer and secondly it helps the immune system to find and kill cancer cells. In this era it has shown lot of promise to increase overall response and survival of the patients. This study explores immunotherapy response in advanced and metastatic cancer patients in [11] . As response rate varies from 15% to 30% in various cancers as per the immunotherapy trails, patients in this study also had similar response rates except in HCC. Small sample size in individual cancer is limiting factor in this study.
Most of our patient had only grade 1 -2 fatigue (60%), where as it was around 12% -24% in various single studies [12] . There was no grade III-IV adverse events observed in the study and no patient were discontinued on treatment due to side effects. In various FDA approved trails for Nivolumab grade III toxicity was 12% -69% and grade IV was 7% -20% [13] [14] . This is one of the Indian study mainly reporting experiences with Nivolumab.
Large sample size is required to conclude about the efficacy of the study.
Nivolumab is more tolerated in Indian patients compare to other reported studies.
